четверг, 11 августа 2011 г.

High Insulin Levels Raise Risk Of Breast Cancer In Postmenopausal Women

Higher-than-normal levels of insulin place postmenopausal women at increased risk of breast cancer, researchers at Albert Einstein College of Medicine of Yeshiva University report. Their findings, published in the January 7 issue of the Journal of the National Cancer Institute, suggest that interventions that target insulin and its signaling pathways may decrease breast cancer risk in these women.


Breast cancer is the most common cancer among women in the United States. Last year, approximately 182,000 women were diagnosed with breast cancer and more than 40,000 died from the disease. The majority of breast cancers arise in women past the age of menopause.


Obesity is a well established risk factor for postmenopausal breast cancer, but just how obesity and breast cancer are connected is unclear. Many researchers have assumed that the link is estrogen a hormone that is known to increase breast-cancer risk and is found at higher-than-average levels in obese women. But obese women also have other hormonal imbalances that may play a role in triggering breast cancer. One such imbalance is elevated levels of insulin, which stimulates the growth of breast cells in tissue culture. The Einstein study is the first to prospectively identify insulin's role in breast cancer while controlling for estrogen levels.


The multi-year Women's Health Initiative (WHI) the largest study of postmenopausal women ever funded by the National Institutes of Health followed health outcomes in more than 93,000 postmenopausal women. At enrollment, each participant donated blood samples that were stored for later analysis.


In 2004, the Einstein researchers selected a subset of more than 1,600 of these participants: 835 who had developed breast cancer during the study, and a random sample of 816 women representative of the WHI as a whole. Using the blood samples and other measurements taken when the women enrolled, the researchers assessed their fasting insulin level, naturally occurring levels of estradiol (a form of estrogen), and body mass index, or BMI (a measure of obesity). After dividing the women into four groups based on their fasting insulin levels and controlling for estrogen levels, the researchers found that women with the highest insulin levels were nearly 50 percent more likely to have developed breast cancer compared with women who had the lowest insulin levels.


Most of this effect was observed in the large subset of women from the WHI study who did not use hormone-replacement therapy. HRT has a strong effect on insulin and other hormonal factors, so eliminating this variable gives a clearer picture of insulin's effect on breast cancer. "Among these women, the influence of insulin on breast cancer risk was quite high," says lead author Marc Gunter, Ph.D., assistant professor of epidemiology & population health at Einstein. "Women with the highest insulin levels in their blood were more than two times more likely to develop breast cancer than women with the lowest insulin levels." Moreover, "when we controlled for insulin, the association between obesity and breast cancer became much weaker," adds Dr. Gunter. "This means that a large component of that obesity-cancer relationship may be mediated by insulin levels."















The findings have important implications for prevention, and possibly treatment, of postmenopausal breast cancer, according to Howard Strickler, M.D., M.P.H, who was senior author of the paper and a professor of epidemiology & population health at Einstein. "Research now needs to focus on ways to reduce insulin's effects on cell growth and replication in the breast while preserving its positive metabolic effects.


There are several possibilities and working with our laboratory collaborators we hope to make fast progress," said Dr. Strickler.


"It is also possible that screening non-diabetic postmenopausal women for high insulin levels could prove useful in identifying individuals at high risk for breast cancer," says Dr. Strickler.


The current study is part of a broader research program at Einstein. Researchers are focusing on how the effects of insulin and insulin-like growth factors on cell replication and survival influence a variety of conditions. "Every cell in the body carries insulin receptors and most carry IGF-1 receptors, so it makes sense that this biologic pathway could play a major role in health and disease across a broad range of conditions and we have to do much more to understand these relationships," notes Dr. Strickler. So far, studies by Dr. Strickler and his colleagues have shown that insulin and/or IGFs also play a role in endometrial and colorectal cancer, as well as the progression of certain viral diseases, including HIV, hepatitis C virus in the liver and human papillomavirus (the cause of cervical cancer).


About Albert Einstein College of Medicine of Yeshiva University


Albert Einstein College of Medicine of Yeshiva University is one of the nation's premier centers for research, medical education and clinical investigation. It is the home to some 2,000 faculty members, 750 M.D. students, 350 Ph.D. students (including 125 in combined M.D./Ph.D. programs) and 380 postdoctoral investigators. Last year, Einstein received more than $130 million in support from the NIH. This includes the funding of major research centers at Einstein in diabetes, cancer, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Through its extensive affiliation network involving five hospital centers in the Bronx, Manhattan and Long Island which includes Montefiore Medical Center, Einstein's officially designated University Hospital the College runs one of the largest post-graduate medical training program in the United States, offering approximately 150 residency programs to more than 2,500 physicians in training. For more information, please visit aecom.yu.edu.


Albert Einstein College of Medicine of Yeshiva University

1300 Morris Park Ave.

Bronx

NY 10461

United States

aecom.yu.edu



View drug information on Estradiol Transdermal System.

четверг, 4 августа 2011 г.

At ASPS Annual Meeting: Innovative 'No Breast Implant' Procedure

Women who desire a mommy-makeover, have had major weight loss, or are unhappy with the toll age has taken on their breasts can breathe easier. An innovative procedure to correct severely deflated, sagging breasts left looking like "pancakes" will be presented at the American Society of Plastic Surgeons (ASPS) Plastic Surgery 2008 conference, Oct. 31 - Nov. 5, in Chicago. The procedure corrects misshapen breasts by lifting and restoring them to a more natural, full shape and position without the use of breast implants.



"In the past several years I've seen more women in their 50s who are unhappy with their breasts," said Dennis Hurwitz, MD, ASPS Member Surgeon and course instructor. "These women have had numerous pregnancies, waited later in life to have children, lost a lot of weight, or simply haven't aged well and want to restore their figure. The breast irregularities these patients share are unique. These are extreme cases - not your 'run of the mill' augmentation patients who simply want to enlarge their breasts from an A to C cup."



The procedure presented at Plastic Surgery 2008 uses unwanted tissue and fat from the patient's tummy, along the bra line, or beneath the upper arm, shapes it into a breast mound and secures it with absorbable sutures into a tissue sheet that acts like a sling to hold the flap into position. This "spiral flap" is mobile enough to permit artistry in shaping, positioning and enlarging the breast. According to Dr. Hurwitz, the breasts are not only enlarged and better-shaped; they are soft and shift naturally with changes in body position. Patients also get the dual benefit of body contouring.



Currently, the majority of these patients are treated with conventional breast surgery, generally with less patient satisfaction. However, the "spiral flap" technique should not be substituted for standard breast implant augmentation, augmentation with breast lift, or breast reduction in all patients. While the procedure may be an option for a small percentage of women (post-pregnancy or as a result of aging) with extremely flattened chests who have ample excess skin around their mid torso, the majority treated with this technique are massive weight loss patients.



"For these women, so much volume and skin elasticity is gone that a basic breast augmentation or lift just doesn't produce optimal results," said Dr. Hurwitz. "By using the patients own tissue, they get a more natural augmentation with the dual benefit of body contouring."







Nearly 348,000 breast augmentations were performed in 2007, making it the number one cosmetic plastic surgery procedure last year, according to ASPS statistics. In addition, more than 106,000 breast reductions and 104,000 breast lifts were performed last year.



The American Society of Plastic Surgeons is the largest organization of board-certified plastic surgeons in the world. Representing more than 6,700 physician members, the Society is recognized as a leading authority and information source on cosmetic and reconstructive plastic surgery. ASPS comprises more than 90 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the Society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada.



Source:ASPS Public Relations


American Society of Plastic Surgeons

четверг, 28 июля 2011 г.

Media Campaign Targets Hispanic Women For Health Care Prevention

The Washington Post on Tuesday profiled American Cancer Society President Elmer Huerta, who uses Spanish-language television and radio to encourage Hispanic women in the U.S. to seek preventive health care. Since 1994, Huerta has starred in the national weekly television program "Hablemos de Salud," or "Let's Talk About Health," which focuses on disease prevention. Huerta, who created the television show, also voices radio spots called "Cuidando Su Salud," or "Taking Care of Your Health," which air daily on more than 120 stations in the U.S. and more than 350 in Latin America. He also hosts a syndicated radio show called "Cita Con el Doctor," or "Appointment With the Doctor."

A recent survey found that about 70% of patients at the Cancer Preventorium -- a clinic at the Washington, D.C.-based Washington Hospital Center that focuses on care for low-income, Hispanic women -- learned about the center from Huerta's programs, So Young Pak, WHS spokesperson said. Since its opening in 1994, the center has treated almost 15,400 women and 6,000 men, leading to 71 diagnosed cancers (Moreno, Washington Post, 5/13).


Reprinted with kind permission from kaisernetwork. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at kaisernetwork/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork, a free service of The Henry J. Kaiser Family Foundation.

© 2008 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

четверг, 21 июля 2011 г.

Advocates Call For Increased Investment In Women, Girls Worldwide To Address Issues Such As HIV/AIDS

Advocates worldwide ahead of International Women's Day on Saturday highlighted issues such as HIV/AIDS, gender equality, discrimination, violence against women and the need to invest in women and girls, the AP/PR-Inside reports.

United Nations Secretary-General Ban Ki-moon on Thursday during a meeting of a U.N. commission on gender equality and advancement of women said that nations should allocate increased resources for health care, nutrition, job opportunities and other needs of women worldwide. "Investing in women helps us fight all the challenges of our time -- from poverty, hunger and illiteracy to environmental degradation and disease, including HIV/AIDS," Ban said (AP/PR-Inside, 3/7). He added that gender equality is a prerequisite for reaching the United Nations Millennium Development Goals by 2015. "As we know from long and indisputable experience, investing in women and girls has a multiplier effect on productivity and sustained economic growth," Ban said, adding, "No measure is more important in advancing education and health, including the prevention of HIV/AIDS. No other policy is as likely to improve nutrition or reduce infant and maternal mortality." Ban also pointed out the success of microfinance programs that lend small loans to women in developing countries and called on nations to "explor[e] effective and innovative ways of investing in women around the world" (AFP/Inquirer, 3/6).

U.N. officials also called on countries to mark International Women's Day with renewed efforts to end sexual assault, forced prostitution and other violence against women. Joanne Sandler, acting director of the United Nations Development Fund for Women, called on member nations to "break new ground in the struggle for women's rights" as they mark the annual event, adding that there is an "urgent need to end violence against women in all of its forms." U.N. Assistant Secretary-General Kathleen Cravero also urged the U.N. Security Council to support an eight-year-old pledge to protect women and girls from rape and sexual abuse during armed conflict. "Rape is a crime and must be stopped," Cravero said (AP/PR-Inside, 3/7).

Secretary of State Condoleezza Rice on Thursday called for increased political roles for women worldwide, the AP/Google reports. Speaking at a conference on women's rights, Rice said, "In today's modern world, no country can achieve lasting success and stability and security if half of its population is sitting on the sidelines." She added that the "international community should make sure that we hear the voices of women and account for their concerns wherever we seek to establish or keep the peace. If we do that, we are actually making the job of keeping the peace easier." Other participants at the conference included Ukrainian Prime Minister Yulia Tymoshenko, Liberian Foreign Minister Olubanke King-Akerele and Egyptian first lady Suzanne Mubarak. European Union External Relations Commissioner Benita Ferrero-Waldner, who hosted the conference, said participants agreed to continue high-level talks to ensure that expanding the roles of women stays at the top of the international agenda (Brand, AP/Google, 3/6).














In related news, Monday is National Women and Girls HIV/AIDS Awareness Day in the U.S. The awareness day is a nationwide initiative that aims to increase awareness about the effect of HIV/AIDS on women and girls in the country through education about safer sex, testing and prevention measures (Plybon, WFMY News 2, 3/10).

ActionAid Report
A report published Friday by ActionAid said that systematic discrimination against girls and women in developing countries will prevent the United Nations from meeting the MDGs, London's Guardian reports. According to the report, girls and women are more likely to experience poverty, hunger, illiteracy and disease, compared with boys and men. According to the report, African women account for 75% of HIV/AIDS cases among young people.

ActionAid said discussions about the MDGs at the United Nations and at this year's meeting of the Group of Eight industrialized nations in Japan will succeed only if they recognize that the "development emergency is first and foremost an emergency for women and girls." According to the Guardian, if current trends continue, the goal of halving hunger will not be met until 2035, and 40 countries will not have equal school enrollment of girls and boys until after 2025. In addition, reducing maternal mortality rates is less than one-fifth of what was needed to meet the MDG target. Laura Turquet, women's rights policy officer of ActionAid, said, "Getting the goals back on track is about more than governments saving face. Fundamentally, it is about women realizing their basic human rights." She added, "As the lack of progress on maternal health shows, people's lives are at stake" (Elliott, Guardian, 3/7).


Reprinted with kind permission from kaisernetwork. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at kaisernetwork/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork, a free service of The Henry J. Kaiser Family Foundation© 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.

четверг, 14 июля 2011 г.

Male Sex Dysfunction Drugs May Show Promise For Females

One needs only turn on the television to understand that significant advances have been made in the cure and treatment of male sexual dysfunction. Less visible progress has been made in understanding and treating female sexual disorders (FSD), a complex and multi-layered problem. A team of researchers has undertaken a new approach in the lab to understanding how and why FSD occurs in general, and the impact of the vasculature (the vessels in the body that carry blood, such as arteries and veins) in particular. The findings of their latest study suggest that the drugs that help men may some day also address some forms of female sexual dysfunction.


The study, Phosphodiesterase Type 5 Inhibitors Relax Female Rat Internal Pudendal Arteries: Potential Treatment for Female Sexual Dysfunction, was conducted by Kyan J. Allahdadi, Rita C. Tostes, and R. Clinton Webb, all of the Medical College of Georgia, Augusta, GA. Dr. Allahdadi and his colleagues are presenting their findings at the 122nd Annual Meeting of the American Physiological Society, which is part of the Experimental Biology 2009 scientific conference. The meeting will be held April 18-22, 2009 in New Orleans.


The Study


New evidence suggests that female sexual dysfunction may be, in part, the result of inadequate supply of blood to the female genitals and may be addressed with erectile dysfunction drugs. Originally developed as therapy for hypertension, these drugs work by dilating blood vessels sufficiently to produce erections in males. These drugs have not been fully explored in females.


The researchers used an animal model and compared the effects of three drugs used for erectile dysfunction (the phosphodiesterase 5 inhibitors (PDE5I, such as Viagra® (sildenafil); Levitra® (vardenafil); and Cialis® (tadalafil)). PDE5I was used and analyzed in female and male rat internal pudendal arteries. The internal pudendal artery supplies blood to the penis in men and to the vagina and clitoris in women. Arterial segments were contracted with phenylephrine then submitted to increasing concentrations of one of the PDE5 inhibitors.


The internal pudendal arteries of both male and female rats (n=10 to12) were measured for constriction/dilation.


Results


The researchers found the following:


Percent maximum relaxation (Top), effective concentration to relax 50% (Bottom)















Sildenafil

Female Arteries Concentration/Dependency: 105.00?±7.73; 6.60?±1.7

Male Arteries Concentration/Dependency: 103?±0.9; 5.67?±0.9


Vardenafil

Female Arteries Concentration/Dependency: 115.6?±11.63; 6.67?±0.24

Male Arteries Concentration/Dependency: 105.1?±89.88; 6.4?±0.23


Tadalafil

Female Arteries Concentration/Dependency: 80.13?±5.39; 7.98?±0.24

Male Arteries Concentration/Dependency: 102.3?±23.65; 5.4?±0.23


-- All the PDE5I inhibitors relaxed both female and male rat internal pudendal arteries, indicating that these arteries from both female and male rats are sensitive to PDE5I. However, female internal pudendal arteries were more sensitive to sildenafil at a lower concentration, which suggests it may be effective at a lower dose than vardenafil.


-- Male internal pudendal arteries reacted more effectively to vardenafil. Female internal pudendal arteries also reacted differently in comparison to the male arteries in that they demonstrated an oscillatory behavior by both dilating and contracting, suggesting that PDE5I may have a different mechanism of action in females.


Conclusions


According to Dr. Allahdadi, "PDE5I may be useful in the treatment of female sexual dysfunction caused by inadequate blood supply through the internal pudendal artery. The significant difference in how male and female pudendal arteries react to PDE5 inhibitors merits further study."


The study team is currently exploring the different relaxation profile observed between female and male rat internal pudendal arteries as well as functional abnormalities in internal pudendal arteries from diabetic rats.


Physiology is the study of how molecules, cells, tissues and organs function to create health or disease. The American Physiological Society has been an integral part of this discovery process since it was established in 1887.


Source: American Physiological Society (APS)



View drug information on Cialis; Levitra; Viagra.

четверг, 7 июля 2011 г.

Far Too Many Women Risking Death to Give Life, UNFPA Leader Says

A world in which a woman risks death each minute in order to bring new life must be transformed, Thoraya Ahmed Obaid, the
Executive Director of UNFPA, the United Nations Population Fund, said today.


"We must create a better, more caring world by doing all we can to prevent millions of our less fortunate sisters from losing
their lives to pregnancy and childbirth, especially when we know how to avoid these tragic deaths," said Ms. Obaid during the
launching of a report on the progress and challenges in attaining the Millennium Development Goals (MDGs) agreed by the
world's leaders in 2000. "Countries have long agreed that no woman should be left to die for lack of reproductive health, and
today's report reaffirms that universal access to reproductive health care, including family planning, is the starting point
for maternal health and saving women's lives."


"Maternal health also frees women to pursue opportunities in work and education, giving them power to make decisions to
improve lives in their families and communities," said Ms. Obaid. "The empowerment of women, as today's report affirms, is
prerequisite to overcoming poverty, hunger and disease, and to achieving all development goals."


"Despite some progress over the last five years, today's report clearly shows that we must do far more to reduce poverty and
save lives around the world," said Ms. Obaid. "Promoting the rights of girls and women, securing their reproductive health
and the means to protect themselves from sexually transmitted infections, particularly HIV/AIDS, are the surest ways to
realize the development goals of all countries, rich or poor."


The Millennium Development Goals Report 2005, Ms. Obaid said, fully underlines the important links between the MDGs and the
Programme of Action of the 1994 Cairo International Conference on Population and Development, which stresses the role of
reproductive health in sustaining lives and fighting poverty.


The lifetime risk of death from pregnancy in the developing world would be reduced substantially if all of its women had
access to the family planning services they desired, according to the report. Currently, it adds, 200 million women have an
unmet need for safe and effective contraceptive services.



If these women used effective contraception, more than 100,000 maternal deaths-one fifth of world totals-could be avoided
each year, according to the World Health Organization.


Today's report says that it is essential for pregnant women who face unexpected complications to get medical care and access
to emergency obstetric care centres that must be stocked with drugs, equipment and supplies.


The Millennium Development Goals Report 2005 also calls for pragmatic and forward-looking approaches to prevent the spread of
HIV/AIDS. "Because there is no cure for AIDS, prevention is essential", it states, adding "treatment and care need to be
expanded to reach millions more," who are HIV-positive.


UNFPA is the world's largest multilateral source of population assistance. Making motherhood safer for all women is at the
heart of the Fund's mandate.


For more information, please contact:

Abubakar Dungus, +1(212) 297-5031, dungusunfpa;

Omar Gharzeddine, +1(212) 297-5028, gharzeddineunfpa;

or visit the UNFPA website, unfpa



Distributed for UNFPA by:


Peter Robbs Consultants Ltd

News Media and Editorial

Main contacts:

Cathy Bartley

T: +44 20 7635 1593

Peter Robbs

T: +44 1480 465328

F: +44 1480 492724

E: cathy.bartleyukonline

E: peter.robbsukonline

четверг, 30 июня 2011 г.

Is It Safe To Use Oral Contraceptives To Eliminate Periods? Harvard Women's Health Watch Explores The Question

The new birth control pill
Lybrel is the first oral contraceptive designed to be taken 365 days a year
with no pill-free intervals. Women who use Lybrel don't have regular
periods, although they may have breakthrough bleeding. There are risks and
benefits to suppressing menstruation, reports the September 2007 issue of
Harvard Women's Health Watch.



The idea of preventing periods is not completely new. Conventional oral
contraceptives also stop periods if they are taken continuously, and a
clinician may suggest this approach to enable a woman to skip her period at
an inconvenient time, such as during her honeymoon. The notion of
suppressing periods over a longer term has become increasingly attractive,
partly because this strategy has helped with treating endometriosis and
managing the hormonal swings of perimenopause.




There's some justification for reducing the number of periods or
eliminating them altogether. For some women, eliminating periods can mean
avoiding cramps, mood swings, headaches, and heavy bleeding that can cause
anemia. On the other hand, many women are uncomfortable with the notion of
not having periods. One concern about Lybrel is that if it fails, a woman
may not know she is pregnant.



The Harvard Women's Health Watch notes that there are no long-term
safety data on Lybrel, but its risks are thought to be similar to
conventional oral contraceptives -- an increased incidence of blood clots,
heart attacks, and stroke, especially in smokers. On the plus side, birth
control pills appear to lower the risk of ovarian and endometrial cancers;
Lybrel might do the same. But the effects of taking Lybrel for more than a
year are unknown. The use of continuous birth control has to be considered
largely uncharted territory.


Harvard Women's Health Watch

health.harvard.edu/women